Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes for Preclinical Cardiotoxicity Screening in Cardio-Oncology.

• hiPSC-CM offer an alternative to in vivo models for predicting cardiotoxicity. • hiPSC-CM monolayers detect pro-arrhythmic effects; inotropic detection is less established. • Cardiac spheroids and engineered tissue may suit chronic cardiotoxicity studies (>2 weeks). • Cardiac assays with non-myocyte cells may be key to identifying some cardiotoxicity forms. • hiPSC-CM technologies are well placed to develop patient-specific assays in the future.